Biodexa ceo issues shareholder letter highlighting progress in 2023 and expected milestones in 2024

Biodexa pharmaceuticals plc (“biodexa” or the “company”) biodexa ceo issues shareholder letter highlighting progress in 2023 and expected milestones in 2024 cardiff, united kingdom, jan. 22, 2024 (globe newswire) – biodexa pharmaceuticals plc (nasdaq: bdrx), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs including type 1 diabetes and rare / orphan brain cancers, today announced that stephen stamp, ceo and cfo of biodexa, has issued a shareholder letter highlighting the company's progress in 2023 and expected milestones in 2024. the full text of the letter follows: dear shareholders, i thought now would be a good time to review our company's progress in 2023 and our plans and expected milestones for 2024, the latter being set out in the following graphic: last year proved to be a year of transition for our company.
BDRX Ratings Summary
BDRX Quant Ranking